INDIA REMOVES EXPORT BAN ON HCQ

INDIA REMOVES EXPORT BAN ON HCQ

India has lifted the export ban on hydroxycholoroquine, the anti – malarial drug

Department of Pharmaceutical has approved the lifting of ban on export of Hydroxychloroquine API as well as formulations

Manufacturers, except export – oriented units and those in special economic zones, would still have to supply 20% of their production to the domestic market

India banned the export of the drug and its formulations in March but eased some of these restrictions in April

IPCA Laboratories and Cadila Healthcare are two leading Indian manufacturers of the drug

Hydroxychloroquine (HCQ): It is a medication used to prevent and treat malaria

 

Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda

Hydroxychloroquine is in the antimalarial and 4-aminoquinoline families of medication 

Side effects may include vomiting, headache, changes in vision, and muscle weakness, allergic reactions, vision problems, and heart problems

Hydroxychloroquine and chloroquine are extremely toxic in overdose.